Clinical Depression (Major Depressive Disorder): A Medical Guide

Clinical depression, the term most people use interchangeably with Major Depressive Disorder (MDD), is a clinically recognized mental health condition defined by the DSM-5 as a persistent depressed mood or loss of interest that causes significant functional impairment. NIMH describes it as symptoms present most of the day, nearly every day, for at least two weeks. Three diagnostic essentials anchor the diagnosis:

• Symptom threshold: At least five of nine DSM-5 symptoms must be present during the same two-week period.
• Duration: Symptoms must persist for a minimum of two weeks, representing a change from previous functioning.
• Functional impairment: The episode must cause clinically significant distress or impairment in work, social relationships, or self-care.

First-line treatment typically includes psychotherapy, antidepressant medication, or both. For moderate to severe cases, combined care consistently outperforms either approach alone.

Table of Contents

• What does “clinical depression” actually mean?
• What are the core symptoms of clinical depression?
• What causes clinical depression and who is at higher risk?
• How do clinicians diagnose major depressive disorder?
• How does clinical depression differ from grief, sadness, and bipolar disorder?
• What are the evidence-based treatments for clinical depression?
• What do PHQ-9 and other screening tools actually tell you?
• When does depression become a mental health emergency?
• What is the typical course and prognosis of clinical depression?
• When are TMS, Spravato, and ECT the right next step?
• Key Takeaways
• The part of clinical depression most people underestimate
• Comprehensive mental health care for depression at Imindmental
• Useful sources and further reading

What does “clinical depression” actually mean?

The phrase “clinical depression” is not a formal DSM-5 diagnosis. Clinicians use it as a plain-language shorthand for Major Depressive Disorder, the precise diagnostic label. You may also encounter the terms major depression and unipolar depression in medical records or research literature. All three refer to the same condition. “Unipolar” simply distinguishes it from bipolar disorder, where depressive episodes alternate with periods of elevated or manic mood.

MDD can present as a single episode or follow a recurrent course, meaning episodes return after periods of full or partial recovery. Many people experience more than one episode across their lifetime, and the risk of recurrence increases with each subsequent episode.

Prevalence matters here. WHO data estimates that depression affects approximately 5.7% of adults globally, with women affected at higher rates than men. That pattern holds across most age groups, though MDD can develop at any stage of life, from adolescence through late adulthood. A note on presentation: men often show irritability or increased risk-taking rather than reported sadness, and children may present with somatic complaints or school avoidance rather than verbalized low mood.

What are the core symptoms of clinical depression?

The DSM-5 diagnostic criteria require at least five of the following nine symptoms, present most of the day, nearly every day, for at least two weeks. One of the five must be either depressed mood or loss of interest:

• Depressed mood most of the day (feeling sad, empty, or hopeless)
• Anhedonia: markedly diminished interest or pleasure in almost all activities
• Sleep disturbance: insomnia or hypersomnia
• Appetite or weight change: significant weight loss or gain, or decreased or increased appetite
• Fatigue or loss of energy nearly every day
• Difficulty concentrating, thinking clearly, or making decisions
• Psychomotor changes: observable slowing (psychomotor retardation) or agitation
• Feelings of worthlessness or excessive, inappropriate guilt
• Recurrent thoughts of death or suicidal ideation, with or without a specific plan

The NHS clinical guidance groups these into psychological, physical, and social symptom clusters, noting that doctors classify severity as mild, moderate, or severe based on symptom burden and functional impact.

If you or someone you know is experiencing active suicidal thoughts, a plan to act, or a recent attempt, this is a medical emergency. Call 911 immediately or go to the nearest emergency department. The 988 Suicide and Crisis Lifeline is available 24/7 by call or text for crisis support.

You can find practical guidance on recognizing signs of clinical depression at Imindmental’s resource library.

What causes clinical depression and who is at higher risk?

MDD is multi-factorial. No single cause explains it, and that matters clinically because treatment often needs to address more than one contributing factor.

Biological contributors include genetic predisposition (a first-degree relative with MDD meaningfully raises your risk), neurobiological changes in serotonin, norepinephrine, and dopamine systems, and emerging evidence around inflammatory pathways and HPA-axis dysregulation. These are not character flaws or signs of weakness. They are measurable physiological changes.

Psychological and social contributors include a history of trauma or adverse childhood experiences, chronic life stress, relationship loss, and social isolation. Persistent stressors do not simply “cause sadness.” Over time, they can alter the brain’s stress-response architecture in ways that meet full MDD criteria.

Common risk factors clinicians assess include:

• Personal or family history of depression or other mood disorders
• Prior depressive episodes (each episode raises recurrence risk)
• Chronic medical illness, particularly cardiovascular disease, diabetes, or chronic pain
• Substance use disorders, which frequently co-occur with MDD
• Certain medications (corticosteroids, beta-blockers, some hormonal therapies)
• Major life transitions or losses

One clinical rule that often surprises patients: always rule out a medical cause first. Thyroid dysfunction, anemia, vitamin B12 deficiency, and certain infections can all produce depressive symptoms that resolve once the underlying condition is treated. A clinician will typically order basic labs before confirming an MDD diagnosis.

How do clinicians diagnose major depressive disorder?

Diagnosis follows a structured process, not a single questionnaire. Here is how it typically unfolds:

1. Clinical interview. A psychiatrist, psychologist, or trained clinician conducts a structured or semi-structured interview covering symptom onset, duration, severity, and functional impact. They also screen for prior manic or hypomanic episodes, psychotic features, substance use, and trauma history.

2. DSM-5 checklist application. The clinician confirms that five or more of the nine core symptoms have been present for at least two weeks, that they represent a change from baseline, and that they cause clinically significant distress or impairment. Symptoms must not be attributable to a substance, medication, or another medical condition.

3. PHQ-9 screening. The Patient Health Questionnaire-9 (PHQ-9) is a widely used, validated nine-item self-report tool that maps directly onto DSM-5 symptom criteria. Clinicians use PHQ-9 scores as a triage and severity signal, and to track treatment response over time. A high score prompts further clinical evaluation; it does not confirm a diagnosis on its own.

4. Medical rule-outs. Lab work typically includes thyroid function tests, a complete blood count, and a metabolic panel. Clinicians also review current medications for depressogenic side effects and screen for substance use.

5. Psychiatric differential. The JAMA clinical review recommends systematic evaluation for self-harm risk, suspected bipolar disorder, psychotic symptoms, substance use, and co-occurring anxiety as part of routine assessment. This step is what distinguishes professional clinical care from a general wellness screen.

6. Severity classification. Once MDD is confirmed, clinicians classify the episode as mild, moderate, or severe based on symptom count, intensity, and functional impact. Severity directly shapes the treatment recommendation.

MedlinePlus also notes the distinction between MDD and persistent depressive disorder (dysthymia): MDD symptoms last at least two weeks at a time, while dysthymia involves a lower-grade but longer-lasting depressed mood, typically persisting for two years or more.

How does clinical depression differ from grief, sadness, and bipolar disorder?

Mayo Clinic is direct on this point: everyday sadness and clinically significant depression are not the same thing. The distinction matters because the treatment path differs substantially.

Grief becomes a clinical concern when it persists beyond expected cultural and individual norms, when it includes persistent suicidal ideation, or when it meets full MDD criteria. The DSM-5 recognizes prolonged grief disorder as a separate diagnosis when grief-specific symptoms remain severe and impairing beyond 12 months (6 months in children).

Red flags for bipolar disorder include a personal or family history of mania or hypomania, mood episodes that cycle rapidly, an unusually early age of onset, or a prior antidepressant trial that triggered elevated mood or agitation. These signs should prompt a full bipolar evaluation before any antidepressant is prescribed, since SSRIs used without a mood stabilizer can precipitate a manic episode in someone with undiagnosed bipolar disorder.

What are the evidence-based treatments for clinical depression?

Treatment selection depends on episode severity, patient preference, prior treatment history, and the presence of comorbidities. The evidence base is substantial.

Psychotherapy options

• Cognitive Behavioral Therapy (CBT): The most studied psychotherapy for depression. CBT targets the relationship between distorted thought patterns and mood, teaching concrete skills to identify and reframe unhelpful thinking. CBT’s evidence base is well-established across multiple meta-analyses.
• Behavioral Activation: Focuses on increasing engagement with rewarding activities to break the withdrawal-avoidance cycle common in depression.
• Interpersonal Therapy (IPT): Addresses relationship patterns, role transitions, and grief as contributors to depressive episodes.
• Problem-Solving Therapy: A structured, short-term approach that builds practical coping skills for managing life stressors.

Antidepressant medications

Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed first-line antidepressants. They include fluoxetine, sertraline, escitalopram, and paroxetine, among others. SSRIs are generally well-tolerated, with a favorable side-effect profile compared to older antidepressant classes. SNRIs (serotonin-norepinephrine reuptake inhibitors, such as venlafaxine and duloxetine) are also first-line options, particularly when pain or fatigue is prominent. Atypical antidepressants like bupropion offer an alternative when sexual side effects or weight gain are concerns.

Detailed guidance on monitoring and adjusting antidepressant therapy is available through Imindmental’s resource on medication management for depression.

Comparative effectiveness: what the evidence shows

A JAMA network meta-analysis of randomized clinical trials provides the clearest summary of effect sizes:

Combined treatment is the standard recommendation for moderate to severe MDD.

Advanced treatments for treatment-resistant depression (TRD)

Treatment-resistant depression is defined clinically as an inadequate response after at least two adequate antidepressant trials at therapeutic doses. When that threshold is reached, clinicians consider:

• Transcranial Magnetic Stimulation (TMS): A non-invasive, FDA-cleared procedure that uses magnetic pulses to stimulate underactive brain regions associated with mood regulation. Delivered in outpatient sessions, typically over several weeks, with no anesthesia required. Learn more about TMS for depression at Imindmental.
• Spravato (esketamine): An FDA-approved intranasal treatment derived from ketamine, administered in a certified clinical setting with a mandatory observation period after each dose. Indicated for treatment-resistant depression and MDD with acute suicidal ideation. Imindmental offers Spravato treatment at its Florida locations.
• Electroconvulsive Therapy (ECT): The most effective intervention for severe, treatment-resistant, or psychotic depression. Requires brief anesthesia and is typically delivered in an inpatient or outpatient hospital setting.

For a comprehensive overview of depression treatment approaches, Imindmental’s guide covers the full spectrum from first-line to advanced care.

What do PHQ-9 and other screening tools actually tell you?

Screening tools are not diagnoses. They are structured starting points that help clinicians and patients have a more precise conversation.

The PHQ-9 asks about the nine DSM-5 symptom domains over the past two weeks, with each item scored by frequency. Clinicians use the total score as a severity signal, a triage guide, and a way to track whether treatment is working over time. A score that falls in a concerning range prompts a full clinical interview; it does not confirm MDD on its own. The PHQ-9 is widely used in primary care, psychiatry, and telehealth settings precisely because it is brief, validated, and maps directly onto diagnostic criteria.

The GAD-7 (Generalized Anxiety Disorder 7-item scale) is frequently administered alongside the PHQ-9 because anxiety disorders co-occur with MDD in a large proportion of patients. Treating depression without addressing co-occurring anxiety often produces incomplete results.

A structured clinical interview, such as the SCID-5 (Structured Clinical Interview for DSM-5 Disorders), remains the gold standard for confirming diagnosis in complex or ambiguous presentations. This is what a psychiatrist or trained psychologist uses when the clinical picture is unclear, when bipolar disorder needs to be ruled out, or when a patient has not responded to initial treatment as expected.

Pro Tip: Before your first psychiatric evaluation, write down your symptoms with approximate start dates, any medications you are currently taking (including supplements), and any prior mental health treatment. This information shortens the assessment process considerably and helps your clinician reach an accurate diagnosis faster.

When does depression become a mental health emergency?

Some presentations of depression require immediate action, not a scheduled appointment. Recognize these emergency signs:

• Active suicidal ideation with a specific plan or intent to act
• A recent suicide attempt
• Severe psychotic symptoms (hallucinations, delusions)
• Complete inability to care for oneself (not eating, not sleeping, unable to function at a basic level)
• Sudden, dramatic worsening of symptoms

What to do:

• Call 911 if there is immediate danger to life.
• Call or text 988 to reach the Suicide and Crisis Lifeline, available 24/7 across the United States for crisis support and emotional assistance.
• Go to the nearest emergency department if you or someone you know cannot be safely managed at home.
• Contact your clinician’s crisis line if you are already in treatment and your provider offers after-hours support.

Safety planning, which involves identifying warning signs, coping strategies, and emergency contacts in advance, is a standard component of care for anyone with MDD and a history of suicidal ideation. Ask your clinician about developing a written safety plan at your next appointment.

What is the typical course and prognosis of clinical depression?

Most people with MDD achieve meaningful symptom improvement with appropriate treatment, though the timeline varies. Many begin to notice changes within four to eight weeks of starting medication or therapy, but full remission often takes longer. Patience and consistent follow-through with the treatment plan matter.

Recurrence is a real clinical concern. Each depressive episode increases the probability of another, and some individuals develop a chronic or partially remitting course. Factors associated with better outcomes include early treatment initiation, strong social support, treatment adherence, and the absence of comorbid substance use. Factors associated with a more difficult course include multiple prior episodes, co-occurring anxiety or personality disorders, chronic medical illness, and ongoing psychosocial stressors.

Practical relapse-prevention strategies include:

• Maintenance antidepressant therapy for at least six to twelve months after remission (longer for recurrent episodes)
• Continuation of psychotherapy even after symptoms improve, to consolidate skills
• Regular follow-up monitoring with a prescriber or therapist
• Lifestyle supports: consistent sleep schedule, regular physical activity, and reduced alcohol use
• Early recognition of warning signs and a clear plan for what to do if symptoms return

When are TMS, Spravato, and ECT the right next step?

Advanced treatments are not a last resort in the pejorative sense. They are a clinically defined next step when standard approaches have not produced adequate relief.

The clinical pathway typically looks like this: a patient completes one or two adequate antidepressant trials (appropriate dose, appropriate duration) without sufficient response. At that point, the treating clinician considers whether TRD criteria are met and whether referral to a specialty clinic is warranted.

Here is how the three main advanced options compare in practice:

• TMS: Best suited for patients who have not responded to one or more antidepressants but do not have severe psychotic features or a need for rapid response. Sessions are outpatient, non-invasive, and typically scheduled five days per week for four to six weeks. No anesthesia, no systemic medication. Imindmental offers Deep TMS therapy at its Florida locations.
• Spravato (esketamine): Indicated for TRD and for MDD with acute suicidal ideation or behavior. Administered as a nasal spray in a certified healthcare setting, with a two-hour post-dose monitoring period required by the FDA’s REMS program. Initial treatment involves twice-weekly sessions for four weeks, then tapering. Imindmental’s Spravato treatment center in Port St. Lucie, Vero Beach, and Stuart provides this service.
• ECT: Reserved for the most severe presentations: psychotic depression, catatonia, acute suicidality requiring rapid response, or repeated failure of multiple medication and stimulation trials. Highly effective but requires anesthesia and is typically hospital-based.

Insurance coverage for TMS and Spravato has expanded significantly, though prior authorization is standard. Bring a complete medication history, documentation of prior treatment trials and responses, and any relevant medical records to an advanced-treatment evaluation. That preparation directly affects how quickly a coverage decision is made.

If you have already tried medications without adequate relief, Imindmental’s resource on what to do when depression medication is not working outlines the clinical next steps clearly.

Pro Tip: When preparing for an advanced-treatment evaluation, document each prior antidepressant by name, dose, duration, and reason for discontinuation. Clinicians need this information to confirm TRD criteria and to avoid repeating trials that have already failed.

Key Takeaways

Clinical depression (MDD) is a diagnosable, treatable medical condition defined by at least five DSM-5 symptoms persisting for two or more weeks with significant functional impairment, and evidence-based treatments from psychotherapy to advanced interventions like TMS and Spravato produce meaningful recovery for most patients.

The part of clinical depression most people underestimate

Depression is frequently described as sadness. That framing, while understandable, misses the most disabling feature of MDD for many patients: the loss of the capacity to feel anything at all. Anhedonia, the inability to experience pleasure or interest, is often what keeps people from seeking help. They do not feel sad enough to justify it. They feel nothing, and nothing feels like a personal failure rather than a symptom.

This matters clinically because anhedonia responds differently to different treatments. Some patients whose mood partially lifts on an SSRI still report flat affect and motivational paralysis. That is not treatment failure. It is a signal that the treatment plan needs adjustment, possibly with an augmentation strategy, a different medication class, or a structured behavioral intervention.

Seeking an evaluation is not an admission that things are beyond repair. It is the most rational response to a condition that, left untreated, tends to worsen and recur. The evidence is clear that treatment works. What varies is finding the right combination for you, and that process is collaborative, not a one-size-fits-all prescription.

If the symptoms described in this article sound familiar, please reach out to a clinician. You do not need to be in crisis to deserve an evaluation.

Comprehensive mental health care for depression at Imindmental

For individuals in Florida navigating a new or returning depressive episode, Imindmental offers a direct path from evaluation to treatment, without long waitlists or fragmented care. The clinic’s psychiatry services cover full diagnostic assessment, medication management, and ongoing monitoring. Psychotherapy is available for individuals, couples, and families, with therapists in Port St. Lucie, Vero Beach, and Stuart. For patients who have not responded to standard antidepressants, Imindmental provides both Deep TMS therapy and Spravato treatment on-site, with insurance verification support included. Telehealth appointments are available for those who prefer to start from home. To schedule a psychiatric evaluation or learn which services fit your situation, visit Imindmental’s conditions and treatment overview or book directly through the site. If you are in crisis right now, call 988 or go to your nearest emergency department.

Useful sources and further reading

The following authoritative sources informed this article and provide reliable further reading on clinical depression:

• Depression — National Institute of Mental Health (NIMH): The U.S. government’s primary resource on MDD, covering definition, symptoms, risk factors, and treatment options with clinical accuracy.
• Management of Depression in Adults: A Review — JAMA: A peer-reviewed clinical review summarizing network meta-analyses of psychotherapy, antidepressant, and combined treatment effect sizes.
• Depressive disorder (depression) — WHO fact sheet: Global prevalence data, demographic patterns, and a summary of evidence-based treatment approaches.
• Major Depressive Disorder — Cleveland Clinic: Patient-facing clinical overview aligned with U.S. provider standards, covering symptoms, diagnosis, and treatment.
• Clinical Depression: What does that mean? — Mayo Clinic: A clear Q&A distinguishing everyday sadness from clinically significant depression, with DSM-5 context.
• Depression — MedlinePlus: NIH-curated resource explaining MDD, persistent depressive disorder, and links to clinical guidelines.
• Symptoms of depression in adults — NHS: Accessible, clinician-aligned symptom list covering psychological, physical, and social dimensions of depression.
• Teen mental health warning signs: a parent’s guide: A practical resource for parents on how depression and mood disorders may present differently in adolescents.

This article provides general health information and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified clinician for personalized assessment and care.

Recommended

• Depression Treatment Approaches: A Complete 2026 Guide
• Chronic Depression Treatment: Your 2026 Complete Guide
• How to Recognize Signs of Clinical Depression
• Depression Treatment: Understanding Symptoms & Finding Help | iMind Mental Health Solutions